PharmaEngine

PharmaEngine Retained Earnings

The Retained Earnings of PharmaEngine (4162.TWO) as of Nov 2, 2026 is 1.48 B TWD. In the previous year, Retained Earnings was 2.13 B TWD — a change of -30.47% (lower).

Retained Earnings

1.48 BTWD

YoY

-30.47%

Last updated:

Retained Earnings of PharmaEngine is 2025 1.48 B TWD. Retained Earnings of PharmaEngine was 2024 2.13 B TWD. It decreases by -30.47% lower compared to the previous year.

The PharmaEngine Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
495.21 M TWD
Jan 1, 2019
337.38 M TWD
Jan 1, 2020
861.94 M TWD
Jan 1, 2021
863.93 M TWD
Jan 1, 2022
658.20 M TWD
Jan 1, 2023
623.44 M TWD
Jan 1, 2024
2.13 B TWD
Jan 1, 2025
1.48 B TWD
The PharmaEngine Retained Earnings history
YEARRetained EarningsYoY
1.48 BTWD-30.47%
2.13 BTWD+241.90%
623.44 MTWD-5.28%
658.20 MTWD-23.81%
863.93 MTWD+0.23%
861.94 MTWD+155.48%
337.38 MTWD-31.87%
495.21 MTWD-29.14%
698.91 MTWD-6.67%
748.85 MTWD+85.68%
403.31 MTWD+226.32%
123.59 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Retained Earnings of PharmaEngine is 1.48 B TWD in 2025.

Retained Earnings of PharmaEngine changed from 2.13 B TWD to 1.48 B TWD, representing a -30.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's PharmaEngine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PharmaEngine

All Key Metrics — PharmaEngine